CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 18,000 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01261273
NCT01261273N/ACompleted

Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients

Terumo Europe N.V.·observational·Posted Dec 16, 2010·Updated Oct 9, 2019

In Brief

An observational study for Coronary Artery Disease. Completed, enrolled 18,000 participants across 257 sites in 32 countries.

Detailed Summary

Title Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the Nobori® DES in real-world patients. Objective Primary objective The primary objective of e-NOBORI registry is to further validate the safety and efficacy of Nobori® DES system in unselected patients representing everyday clinical practice. Primary Endpoint: Freedom from Target Lesion Failure (TLF) defined as a composite of cardiac death, target vessel related myocardial infarction (MI) and clinically driven target lesion revascularization (TLR) at 1 year

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Bangladesh, Belarus, Brazil, Bulgaria, Chile, Czechia, Denmark, Egypt, Estonia, France, Georgia, Germany, Hungary, Indonesia, Ireland, Israel, Latvia, Lithuania, Malta, Mexico, Netherlands, Poland, Romania, Russia, Serbia, Slovenia, Spain, Sweden, Taiwan, Ukraine, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 16, 2010
Enrollment StartAug 25, 2010
Primary CompletionMay 1, 2016
Study CompletionMay 27, 2016
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 15.5 years ago